206650.KQ
EuBiologics Co., Ltd.
KOE · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 8,690.00
−2.80%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 122.3B | 149.2B | 96.0B | 69.4B | 55.5B |
| Cost of Revenue | 51.4B | 63.8B | 40.1B | 35.4B | 31.9B |
| Gross Profit | 70.9B | 85.4B | 56.0B | 34.0B | 23.6B |
| Operating Expenses | |||||
| R&D Expense | 15.8B | 13.2B | 13.0B | 17.9B | 15.8B |
| SG&A Expense | 6.2B | 4.6B | 3.4B | 3.4B | 3.2B |
| General & Admin Expense | 1.6B | 2.4B | 1.7B | 1.5B | 1.4B |
| Selling & Marketing Expense | 1.9B | 2.2B | 1.7B | 1.9B | 1.8B |
| Other Expenses | 8.7B | 6.9B | 5.2B | 5.0B | 8.4B |
| Total Operating Expenses | 26.2B | 24.7B | 21.6B | 26.3B | 27.4B |
| Cost and Expenses | 77.7B | 88.5B | 61.7B | 61.7B | 59.2B |
| Operating Income (EBIT) | 43.3B | 60.7B | 34.3B | 7.7B | (3.8B) |
| Non-Operating | |||||
| Interest Income | 2.0B | 1.6B | 416.2M | 164.7M | 230.8M |
| Interest Expense | 807.3M | 994.4M | 1.1B | 1.1B | 508.3M |
| Net Interest Income | 1.2B | 571.4M | (722.4M) | (890.2M) | (277.5M) |
| Other Non-Op Income/Expense | (333.6M) | (6.9B) | (15.9B) | (22.3B) | 430.5M |
| Non-Operating Income (excl Interest) | 2.2B | — | 14.7B | 21.3B | (1.3B) |
| EBT (Pre-Tax Income) | 43.0B | 53.8B | 18.5B | (14.6B) | (3.3B) |
| Income Tax Expense | 14.0B | 12.5B | (534.5M) | 745.0M | 99.2M |
| Bottom Line | |||||
| Net Income | 29.0B | 41.3B | 19.0B | (13.9B) | (1.1B) |
| Earnings from Cont. Ops | 29.0B | 41.3B | 19.0B | (15.4B) | (3.4B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 29.0B | 41.3B | 19.1B | (13.9B) | (1.1B) |
| Per Share | |||||
| Basic EPS | ₩791 | ₩1,127 | ₩524 | (₩381) | (₩30) |
| Diluted EPS | ₩789 | ₩1,125 | ₩524 | (₩381) | (₩30) |
| Revenue Per Share | ₩3,330 | ₩4,068 | ₩2,631 | ₩1,903 | ₩1,524 |
| Shares | |||||
| Basic Shares Outstanding | 36.7M | 36.7M | 36.5M | 36.4M | 36.4M |
| Diluted Shares Outstanding | 36.8M | 36.7M | 36.5M | 36.4M | 36.4M |
| Profitability Metrics | |||||
| EBITDA | 57.1B | 70.7B | 29.7B | (4.4B) | 5.4B |
| D&A | 10.2B | 10.0B | 10.1B | 9.2B | 7.9B |
| EBIT | 44.7B | 60.7B | 19.6B | (13.6B) | (2.5B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026